This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Alimera Sciences | |
|---|---|
| Name | Alimera Sciences |
| Type | Public |
| Industry | Pharmaceutical |
| Founded | 2003 |
| Headquarters | Alpharetta, Georgia, United States |
| Key people | Richard Hollis, Roopal Shah |
| Products | ILUVIEN |
| Revenue | (varies) |
| Website | (omitted) |
Alimera Sciences is a specialty pharmaceutical company focused on ophthalmic therapies and retinal diseases. The company develops treatments for retinal disorders and commercializes implantable devices and pharmaceuticals across multiple markets, with a focus on chronic conditions affecting vision. Its activities intersect with regulatory agencies, academic research centers, and commercial partners in the biotechnology and medical device sectors.
Founded in 2003, the company was established amid shifts in the biotechnology sector following trends seen at firms such as Genentech, Amgen, Biogen, Gilead Sciences and Regeneron Pharmaceuticals. Early strategic decisions paralleled transactions in the industry, comparable to mergers and licensing arrangements involving Pfizer, GlaxoSmithKline, Novartis, Roche and Eli Lilly and Company. Leadership transitions and capital raises reflected investor activity similar to that around Nasdaq-listed peers and echoing corporate governance developments at Bristol-Myers Squibb and Merck & Co.. The company navigated intellectual property and market-entry challenges resembling disputes seen with Bayer and Johnson & Johnson while engaging clinical collaborators at institutions like Massachusetts General Hospital, Moorfields Eye Hospital, Bascom Palmer Eye Institute, Johns Hopkins Hospital and Wills Eye Hospital.
The lead product is an intravitreal, non-biodegradable fluocinolone acetonide implant for chronic retinal disease, developed through research programs akin to drug-device combinations from Boston Scientific and Abbott Laboratories. Development programs involved partnerships resembling alliances between AstraZeneca and academic laboratories, and trial designs informed by insights from committees such as those convened by American Academy of Ophthalmology and Association for Research in Vision and Ophthalmology. Pipeline considerations reference comparative therapeutic approaches pursued by Regeneron Pharmaceuticals for anti-VEGF therapies, by Allergan for ocular drug delivery, and by Alcon for surgical adjuncts.
Regulatory strategy included submissions to authorities comparable to filings with the U.S. Food and Drug Administration and interactions with agencies analogous to the European Medicines Agency and national competent authorities in United Kingdom, France, Germany, Italy and Spain. Clinical trials were designed with endpoints and monitoring standards similar to studies overseen by ClinicalTrials.gov registries and guided by Good Clinical Practice frameworks used by World Health Organization and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The company reported outcomes in peer-reviewed venues alongside investigators from institutions such as University of Oxford, University of Cambridge, Harvard Medical School, Stanford University School of Medicine and Columbia University Irving Medical Center.
Commercial efforts involved specialty salesforce deployment in markets comparable to launches by Novartis for ophthalmology products and market development strategies similar to Sanofi and Teva Pharmaceutical Industries. Distribution and reimbursement negotiations mirrored engagements with payers and health technology assessment bodies such as National Institute for Health and Care Excellence, regional authorities in Germany and France, and private insurers in the United States. The company pursued partnerships and licensing arrangements with entities comparable to those formed by Shire and Takeda Pharmaceutical Company to expand access in markets including the European Union, United States, and select markets in Asia and Latin America.
Board composition and executive appointments reflected patterns seen at publicly traded biotech firms listed on exchanges like Nasdaq and the New York Stock Exchange. Governance practices aligned with investor expectations shaped by institutional stakeholders such as BlackRock, Vanguard Group, and activist episodes resembling interventions by firms like Elliott Management at other healthcare companies. Leadership included executives with backgrounds at corporations such as Pfizer, GlaxoSmithKline, Johnson & Johnson, Novartis and academic affiliations with Emory University and Yale School of Medicine.
Financial results featured revenues tied to product sales, licensing fees, and partnership milestone payments similar to revenue streams reported by peers including Alnylam Pharmaceuticals and Ionis Pharmaceuticals. Funding rounds and public offerings echoed capital markets activity observed with companies like Moderna and Vertex Pharmaceuticals, and financial reporting practices adhered to standards used by U.S. Securities and Exchange Commission registrants and auditors from firms in the Big Four accounting firms.
Legal and regulatory disputes involved patent, reimbursement, and marketing matters comparable to litigation encountered by Merck Sharp & Dohme, AbbVie, and Bayer. The company engaged in contested proceedings and negotiations reminiscent of intellectual property cases before courts such as the United States District Court for the Northern District of Georgia and administrative reviews similar to appeals heard by national agencies in Italy and Spain. Public scrutiny and media coverage paralleled reporting on controversies involving product labeling and payer access seen with Roche and Allergan.
Category:Pharmaceutical companies Category:Biotechnology companies Category:Ophthalmology